Literature DB >> 8354771

A study comparing paroxetine placebo and imipramine in depressed patients.

J P Feighner1, J B Cohn, L F Fabre, R R Fieve, J Mendels, R K Shrivastava, G C Dunbar.   

Abstract

These data provide evidence for the antidepressant efficacy of paroxetine. Paroxetine- and imipramine-treated patients were significantly different from placebo-treated patients, but little different to each other, on all depressive outcome measures. However, paroxetine appeared to have a possibly greater and earlier beneficial effect on anxiety symptoms associated with depression, when compared with imipramine. Both active therapies were effective in treating patients with severe depression. Side effects for paroxetine were typical of other serotonin (5-HT) uptake inhibitors but different from those of imipramine. In particular, anticholinergic and cardiovascular symptoms were reduced, and premature withdrawal less likely.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8354771     DOI: 10.1016/0165-0327(93)90035-i

Source DB:  PubMed          Journal:  J Affect Disord        ISSN: 0165-0327            Impact factor:   4.839


  15 in total

Review 1.  Randomized, placebo-controlled trials of antidepressants for acute major depression: thirty-year meta-analytic review.

Authors:  Juan Undurraga; Ross J Baldessarini
Journal:  Neuropsychopharmacology       Date:  2011-12-14       Impact factor: 7.853

Review 2.  Evidence b(i)ased medicine--selective reporting from studies sponsored by pharmaceutical industry: review of studies in new drug applications.

Authors:  Hans Melander; Jane Ahlqvist-Rastad; Gertie Meijer; Björn Beermann
Journal:  BMJ       Date:  2003-05-31

Review 3.  Systematic Review and Meta-Analysis: Dose-Response Relationship of Selective Serotonin Reuptake Inhibitors in Major Depressive Disorder.

Authors:  Ewgeni Jakubovski; Anjali L Varigonda; Nicholas Freemantle; Matthew J Taylor; Michael H Bloch
Journal:  Am J Psychiatry       Date:  2015-11-10       Impact factor: 18.112

4.  Does study design influence outcome?. The effects of placebo control and treatment duration in antidepressant trials.

Authors:  Bret R Rutherford; Joel R Sneed; Steven P Roose
Journal:  Psychother Psychosom       Date:  2009-03-24       Impact factor: 17.659

5.  Adverse effects associated with selective serotonin reuptake inhibitors and tricyclic antidepressants: a meta-analysis.

Authors:  E Trindade; D Menon; L A Topfer; C Coloma
Journal:  CMAJ       Date:  1998-11-17       Impact factor: 8.262

Review 6.  Paroxetine. An update of its pharmacology and therapeutic use in depression and a review of its use in other disorders.

Authors:  N S Gunasekara; S Noble; P Benfield
Journal:  Drugs       Date:  1998-01       Impact factor: 9.546

7.  Effects of acute and chronic antidepressant treatments on memory performance: a comparison between paroxetine and imipramine.

Authors:  Laurent Naudon; Maïté Hotte; Thérèse M Jay
Journal:  Psychopharmacology (Berl)       Date:  2007-01-12       Impact factor: 4.530

8.  Sleep improvement is associated with the antidepressant efficacy of repeated-dose ketamine and serum BDNF levels: a post-hoc analysis.

Authors:  Mingqia Wang; Bin Zhang; Yangling Zhou; Chengyu Wang; Wei Zheng; Weijian Liu; Yanni Zhan; Xiaofeng Lan; Yuping Ning
Journal:  Pharmacol Rep       Date:  2021-01-02       Impact factor: 3.024

9.  Treatment discontinuation with selective serotonin reuptake inhibitors compared with tricyclic antidepressants: a meta-analysis.

Authors:  I M Anderson; B M Tomenson
Journal:  BMJ       Date:  1995-06-03

Review 10.  Paroxetine: a review.

Authors:  M Bourin; P Chue; Y Guillon
Journal:  CNS Drug Rev       Date:  2001
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.